SCHEMBL5755306

SCHEMBL5755306

COC(=O)c1ccc(O[C@@H](C)C(=O)OC)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.60
KMT2A Q03164 7/20 0.55
HIF1A Q16665 2/20 0.50
EPAS1 Q99814 2/20 0.50
TSHR P16473 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
LMNA P02545 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 3/20 0.48
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3132688 0.89 MAPT (0.62) MAPTKMT2AHIF1AEPAS1TSHR
SCHEMBL6276416 0.89 MAPT (0.62) MAPTKMT2AHIF1AEPAS1TSHR
SCHEMBL13270866 0.88 MAPT (0.54) MAPTKMT2AHIF1AEPAS1TSHR
SCHEMBL6568018 0.86 MAPT (0.66) MAPTKMT2ATSHRALDH1A1MAPK1
SCHEMBL3470599 0.84 MAPT (0.64) MAPTKMT2ATSHRALDH1A1MAPK1
SCHEMBL13270596 0.84 MAPT (0.56) MAPTKMT2AHIF1AEPAS1TSHR
Veratric Acid Methyl Ester SCHEMBL29573244 0.82 MAPT (0.86) MAPTKMT2ATSHRALDH1A1LMNA
Veratric Acid Methyl Ester SCHEMBL2050732 0.82 MAPT (0.86) MAPTKMT2ATSHRALDH1A1LMNA
SCHEMBL3738587 0.81 MAPT (0.64) MAPTKMT2ATSHRMAPK1LMNA
SCHEMBL18031241 0.81 MAPT (0.59) MAPTKMT2ATSHRALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663234-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS Pfizer Limited (GB) 2006-06-07 EP disclosed
WO-2005121094-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTI-HIV-AGENTS PFIZER LIMITED (GB) 2005-12-22 WO disclosed
US-20050043300-A1 Piperazine derivatives PFIZER INC. 2005-02-24 US disclosed
WO-2005016344-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS PFIZER LIMITED (GB) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043300-A1 Piperazine derivatives CD4, CCR5, RRP15 MAPT 2428/4885KMT2A 2921/4885HIF1A 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.